Every material Form 8-K BioRestorative Therapies, Inc. has filed with the SEC since September 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BioRestorative Therapies, Inc. appointed Donald J. Currie as a Class I director effective October 7, 2026, filling the seat vacated by Katharyn Field's resignation effective August 31, 2026. Mr. Currie also joined the Nominating and Corporate Governance and Compensation Committees, and the Board deemed him independent under Nasdaq rules. The change is a routine board appointment with no financial results or guidance included.
Donald J. Currie appointed Class I director on October 7, 2026, serving until the 2027 annual meeting
Currie added to the Compensation Committee and Nominating and Corporate Governance Committee
Currie to receive a cash fee of CAD $2,000 per month and will not join the standard non-employee director compensation program
BioRestorative Therapies received a notice on September 4, 2026 from Mr. Silva resigning as Vice President of Research and Development and from any other officer positions, effective immediately. The notice claims Good Reason and a Change in Control, and Mr. Silva has demanded severance, which the board has not accepted. The dispute and an ongoing board-directed investigation into the related employment agreements could create legal and financial uncertainty for shareholders.
Resignation notice received September 4, 2026; effective immediately
Mr. Silva claims cash severance of approximately $1.29 million, plus equity acceleration and benefits, if the Good Reason claim is upheld
Board acknowledged the resignation for records purposes but does not accept the Employment Agreement or the Good Reason and Change in Control claims, and has reserved all rights
Pending investigation, no payments under the agreement other than accrued salary and legally required amounts
BioRestorative Therapies filed a Nevada certificate of change for a 1-for-20 reverse stock split of its common stock, effective 4:30 p.m. Eastern on September 7, 2026, with the Board approving it on August 27, 2026 without stockholder approval. The company says the split is intended to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, and that each stockholder's ownership percentage will remain unchanged apart from fractional share rounding.
Every 20 shares of common stock will become one share; trading on a split-adjusted basis begins September 8, 2026 under BRTX with new CUSIP 090655705.
Shares outstanding will fall from 27,622,556 to approximately 1,381,128, and authorized common shares will drop from 1,500,000,000 to 75,000,000.
The split is intended to regain compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BioRestorative Therapies, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →